Navigation Links
VisEn Announces Commercial Launch of IntegriSenseTM Fluorescence Molecular Imaging Agent

- First Product Developed from the VisEn-Merck & Co., Inc. Biomarker Imaging Program -

- Expands VisEn's Leading Fluorescence Molecular Imaging Agent Portfolio and Broadens Applications in Key Areas of Disease Research and Drug Development -

BEDFORD, Mass., Aug. 19 /PRNewswire/ -- VisEn Medical, Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today the commercial launch of its IntegriSenseTM fluorescence in vivo imaging agent product line. The agent is the first product developed out of the Merck-VisEn Biomarker Imaging research collaboration announced in 2007, and will enable researchers to image and assess the role of integrin alpha v beta 3 in disease progression and therapeutic response in vivo.

IntegriSense is an optimized in vivo fluorescence imaging agent targeting integrin alpha v beta 3, a key biomarker closely associated with disease-related vascularity and angiogenesis. The agent was developed to enable in vivo imaging of integrin alpha v beta 3 expression in order to measure and monitor aspects of disease progression and therapeutic response in disease states including oncology, cardiovascular disease, and bone disease.

"The integrin alpha v beta 3 protein plays an important key role in many disease pathways, which is one of the key reasons we selected this as a first imaging target with our collaborators at Merck," said Kirtland Poss, President and CEO of VisEn Medical. "IntegriSense should enable researchers to drive valuable new insights into disease progression and therapeutic mechanisms of action in vivo. We are pleased to be providing our customers the continually expanding ability to generate such rich information on their disease biologies and pathways of interest."

VisEn's in vivo fluorescence imaging technologies, including its Fluorescence Agent Portfolio and its Fluorescence Molecular Tomographic Imaging Systems (FMT), provide the industry's most robust fluorescence molecular imaging performance in identifying, characterizing and quantifying ranges of disease biomarkers in vivo. All of the VisEn imaging agents are designed for use with VisEn's Quantitative Tomographic FMT imaging systems to enable quantitative data on biological targets in vivo. They are also compatible with a range of additional fluorescence imaging systems, including planar systems and intravital microscopes.

Additional product information can be obtained by calling Customer Support at VisEn Medical: 781-932-6875, ext. 315, via email at:; or at

About VisEn Medical

VisEn Medical develops and commercializes the industry's highest performing fluorescence in vivo imaging technology platforms, from research through medicine. Founded in 2000 based on fluorescence in vivo imaging technologies developed by industry-leading researchers and clinicians at the Massachusetts General Hospital and Harvard Medical School, VisEn's FMT Fluorescence Tomography imaging systems and suite of molecular imaging agents are used to quantify biological mechanisms of disease and therapeutic response in vivo. These systems are widely used by leading research institutions and pharmaceutical companies in disease areas including oncology, inflammation, cardiovascular, skeletal and pulmonary diseases. The Company also works with pharmaceutical and clinical partners to design and develop ranges of tailored molecular imaging agents and applications that are targeted to their specific pre-clinical and clinical research areas. For further information please visit

SOURCE VisEn Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
2. VisEn Medical Raises $7 Million in Series B Financing
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
6. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
7. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
8. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
(Date:10/10/2017)... ... 2017 , ... Dr. Bob Harman, founder and CEO of VetStem Biopharma, ... The event entitled “Stem Cells and Their Regenerative Powers,” was held on ... DVM, MPVM was joined by two human doctors: Peter B. Hanson, M.D., Chief of ...
(Date:10/10/2017)... PITTSBURGH, PA (PRWEB) , ... October 10, 2017 ... ... this year’s recipients of 13 prestigious awards honoring scientists who ... be presented in a scheduled symposium during Pittcon 2018, the world’s leading conference ...
(Date:10/9/2017)... ... October 09, 2017 , ... The Giving Tree ... products targeting the needs of consumers who are incorporating medical marijuana into their ... Phoenix, Arizona. , As operators of two successful Valley dispensaries, The Giving Tree’s ...
(Date:10/7/2017)...  The 2017 Nobel Prize in Chemistry recognizes ... Joachim Frank and Richard Henderson ... (cryo-EM) have helped to broaden the use ... The winners worked with systems manufactured by Thermo ... resolved, three-dimensional images of protein structures that lead ...
Breaking Biology Technology:
(Date:10/4/2017)... , Oct. 4, 2017  GCE Solutions, a global clinical ... data and document anonymization solution on October 4, 2017. Shadow is ... field to comply with policy 0070 of the European Medicines Agency ... data. ... GCE Solutions ...
(Date:8/15/2017)... , Aug. 15 2017   ivWatch LLC , a ... intravenous (IV) therapy, today announced receipt of its ISO 13485 Certification, ... by the International Organization for Standardization (ISO®). ... ivWatch Model 400 Continuous Monitoring device for the early ... "This is an ...
(Date:6/30/2017)... , June 30, 2017 Today, ... developer and supplier of face and eye tracking ... Featured Product provider program. "Artificial ... innovative way to monitor a driver,s attentiveness levels ... from being able to detect fatigue and prevent ...
Breaking Biology News(10 mins):